CAPSTONE-1
Baloxavir in Uncomplicated Influenza
Doente / População Intervenção / Exposição Comparação Desfecho
In 1,436 outpatients aged 12–64 with uncomplicated influenza, a single dose of baloxavir shortened time to symptom alleviation compared with placebo with much faster viral-load decline.
N
1436
Desenho
Double-blind RCT
Desfecho
Time to alleviation of symptoms
Relevância
3
ResultadoMedian 53.7 h vs 80.2 h (p<0.001). Treatment-emergent PA-I38T/M/F polymerase substitutions in 9.7 % of baloxavir recipients.
Hayden FG, et al. N Engl J Med. 2018;379(10):913-923. 10.1056/NEJMoa1716197
Discussão e crítica
First single-dose, novel-class anti-influenza — used in selected outpatients; resistance signal warrants monitoring.